Published on 5 Mar 2024 on Zacks via Yahoo Finance

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED Corporation CNMD is well poised for growth in the coming quarters, courtesy of its broad product spectrum. The optimism, led by the solid fourth-quarter 2023 performance and a potential General Surgery, is expected to contribute further. However, headwinds from supply-chain constraints and data security threats persist.

This currently Zacks Rank #3 (Hold) company’s shares have lost 15.2% in the past year against the industry’s 3.2% growth. The S&P 500 Index has increased 24.8% in the same time frame.

CONMED, the renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $2.46 billion. The company projects 25.4% growth over the next five years and expects to maintain its strong performance going forward.